The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The monoamine hypothesis of depression posits that an imbalance in monoaminergic neurotransmission is causally related to the clinical features of depression. Antidepressants influencing serotonin mainly aim at raising serotonin concentrations, thereby increasing serotonergic transmission at the level of the synapse, for example by inhibiting the serotonin transporter. However, the serotonin system is multifaceted. Different serotonin receptor subtypes turn the serotonergic system into a complex neurochemical arrangement that influences diverse neurotransmitters in various brain regions. Classical antidepressants as well as other psychopharmacological agents have various crucial effects on serotonin receptors. We aim at providing a clinically useful characterization of serotonin receptor subtypes in the treatment of depression. Clarifying the mode of action and the interplay of serotonin receptors with pharmacological agents should help antidepressant mechanisms and typical side effects to be better understood. Against this background, we feature the novel antidepressants vortioxetine, vilazodone and milnacipran/levomilnacipran with regard to their serotonin receptor targets such as the 5-HT1A, 5-HT3 and 5-HT7 which may account for their specific effects on certain symptoms of depression (e.g. cognition and anxiety) as well as a characteristic side-effect profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 1×
“Major depressive disorder (MDD) is a very common mental health problem, with an estimated lifetime prevalence ranging from approximately 16% to 18%, and 12-month prevalence rates of 6–8% (Kessler et al., 2003).”
BackgroundSerotonin signalling in the gut: functions, dysfunctions and therapeutic targets
Mawe, G. M., & Hoffman, J. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.105 · Cited by 1,165
Ruhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542 · cited 1×
“Research on the prevalence of sexual dysfunction with SSRIs range from 40% to 70% (Clayton et al., 2002).”
BackgroundMeyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 1×
“By contrast, SSRIs and serotonin–norepinephrine reuptake inhibitors (SNRIs) require higher SERT occupancies of at least 80% to exert their antidepressant effects (Meyer et al., 2004).”
BackgroundDopamine and serotonin: influences on male sexual behavior
Hull, E. M., Muschamp, J. W., & Sato, S. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.08.018 · Cited by 465 · cited 1×
“Although stimulation of some subtypes of serotonin receptors as 5-HT2C (erection) or 5-HT1A (ejaculation) may facilitate sexual behaviours, central effects of serotonin in general are inhibitory, most likely via decreased dopamine release (Hull et al., 2004).”
BackgroundKatona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445 · cited 3×
“…placebo-controlled 6–8- week studies (e.g. Alvarez et al., 2012; Baldwin et al., 2012; Jain et al., 2013), including one study of elderly subjects (Katona et al., 2012) and one positive maintenance study of adults (Baldwin et al., 2012) which have demonstrated the efficacy of vortioxetine in MDD…”
BackgroundInfluentialMcIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
The CRF system, stress, depression and anxiety—insights from human genetic studies
Binder, E. B., & Nemeroff, C. B. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.141 · Cited by 379
Cited by
Neurobehavioral comorbidities of epilepsy: Role of inflammation
Mazarati, A. M., Lewis, M. L., & Pittman, Q. J. (2017) · Epilepsia · doi:10.1111/epi.13786 · Cited by 96
A systematic review of cognitive effects of exercise in depression
Brondino, N., Rocchetti, M., Fusar‐Poli, L., Codrons, E., Correale, L., Vandoni, M., Barbui, C., & Politi, P. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12690 · Cited by 94
Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant
Sowa-Kućma, M., Pańczyszyn-Trzewik, P., Misztak, P., Jaeschke, R. R., Sendek, K., Styczeń, K., Datka, W., & Koperny, M. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.01.030 · Cited by 86
Turner, D., Briken, P., Grubbs, J., Malandain, L., Mestre-Bach, G., Potenza, M. N., & Thibaut, F. (2022) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2022.2134739 · Cited by 86
Hu, P., Wang, D., Zhang, Y., Cai, Z., Ye, T., Tong, L., Xu, X., Lu, J., Liu, F., Lu, X., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108054 · Cited by 61
Metadata
- Authors
- Köhler, S., Cierpinsky, K., Kronenberg, G., & Adli, M.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-01
- Volume
- 30
- Issue
- 1
- Pages
- 13-22
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2339700702
- Cited by
- 138
- References
- 18
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. https://app.cochat.ai/papers/10.1177/0269881115609072
- The paper
- Köhler, S., Cierpinsky, K., Kronenberg, G., & Adli, M. (2016). The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. Journal of Psychopharmacology. https://doi.org/10.1177/0269881115609072
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.